9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

Core Knowledge: Post-burn pruritus (itch) is one of the most pervasive, distressing, and intractable long-term sequelae of thermal trauma, afflicting $>80%\text{ to }90%$ of burn survivors. Far from a mere superficial nuisance, severe post-burn itch impairs physical rehabilitation, disrupts sleep architecture, causes profound psychological anguish, and provokes uncontrollable scratching that shears fragile neo-epithelium, avulses newly placed autografts, and inoculates pathogenic bacteria into healing wounds.

---

1. Dual Mechanisms: Histaminergic vs. Neuropathic Pruritus

Effective treatment requires understanding that post-burn pruritus is not a static symptom driven solely by histamine. Instead, it evolves across the wound healing trajectory from an acute histaminergic/inflammatory phase to a chronic neuropathic/central sensitization phase.

                    DUAL PATHOPHYSIOLOGY OF POST-BURN PRURITUS
  ┌────────────────────────────────────────────────────────────────────────┐
  │ 1. EARLY PHASE: HISTAMINERGIC / INFLAMMATORY PRURITUS                  │
  │    (Wound Closure & Proliferative Phase: Days to Weeks)                │
  │    • Massive dermal mast cell accumulation & degranulation             │
  │    • Mediators: Histamine, Substance P, Serotonin (5-HT), Prostaglandins│
  │    • Activation of unmyelinated polymodal C-fiber pruriceptors         │
  │    • Response: Readily responsive to oral H1/H2 antihistamines        │
  ├────────────────────────────────────────────────────────────────────────┤
  │ 2. LATE PHASE: NEUROPATHIC / CENTRAL PRURITUS                          │
  │    (Scar Maturation & Remodeling Phase: Months to Years)               │
  │    • Aberrant, disorganized sprouting of regenerating C-nerve fibers   │
  │    • Lowered mechanical/thermal activation thresholds (Hyperknesis)    │
  │    • Loss of inhibitory spinal interneurons (Central Sensitization)    │
  │    • Painless stimuli (clothing friction) felt as severe itch (Alloknesis)│
  │    • Response: REFRACTORY to antihistamines alone; REQUIRES GABAPENTIN │
  └────────────────────────────────────────────────────────────────────────┘

Comparing the Two Clinical Pruritus Paradigms:

---

2. The Stepwise Multimodal Management Ladder (ABA Practice Guidelines)

Because no single agent eradicates post-burn itch, the American Burn Association (ABA) endorses a stepwise multimodal ladder. Therapies are combined synergistically to target peripheral mast cells, cutaneous nerve endings, and central spinal pathways.

                     STEPWISE MULTIMODAL PRURITUS LADDER
  ┌────────────────────────────────────────────────────────────────────────┐
  │ STEP 4: Specialized Systemic & Topical Refractory Adjuncts             │
  │ • Topical Doxepin 5%, Capsaicin 0.025%, Topical Lidocaine 4–5%         │
  │ • Systemic Ondansetron (5-HT3), Naltrexone (μ-opioid), SSRIs/Sertraline│
  │ • Fractional CO2 / Pulsed Dye Laser, TENS neuromodulation              │
  ├────────────────────────────────────────────────────────────────────────┤
  │ STEP 3: Central Neuropathic Modulators (First-Line for Chronic Itch)   │
  │ • Gabapentin (Neurontin): 300 mg TID titrated up to 1800–2400 mg/day   │
  │ • Pregabalin (Lyrica): 75–150 mg PO BID (alternative to gabapentin)    │
  ├────────────────────────────────────────────────────────────────────────┤
  │ STEP 2: Combination Oral Antihistamines                                │
  │ • Daytime H1: Cetirizine (10–20 mg/day) or Fexofenadine (180 mg/day)   │
  │ • Nighttime H1: Hydroxyzine (25–50 mg qHS) or Diphenhydramine (50 mg)  │
  │ • Adjunctive H2: Famotidine (20 mg BID) or Cimetidine (400 mg BID)     │
  ├────────────────────────────────────────────────────────────────────────┤
  │ STEP 1: Foundational Skin Barrier Restoration & Non-Pharmacological    │
  │ • Unscented, high-lipid emollients (petrolatum/ceramides) 3–5x daily   │
  │ • Tepid bathing, mild soap-free cleansers, cool compresses             │
  │ • Loose soft cotton clothing, short fingernails, cotton sleep gloves   │
  └────────────────────────────────────────────────────────────────────────┘

---

3. Step 1: Foundational Barrier Hydration & Non-Pharmacological Care

Burned skin, newly healed graft sites, and donor areas lack functional sebaceous and eccrine glands, resulting in profound xerosis (dryness) and a defective stratum corneum lipid barrier. Severe xerosis drastically lowers cutaneous itch thresholds.

Essential Nursing Interventions:

1. Aggressive Emollient Therapy:
   • Apply thick, fragrance-free, high-lipid moisturizers (e.g., white petrolatum, mineral oil-based ointments, ceramide creams, or colloidal oatmeal formulations) 3 to 5 times daily.
   • Reapply immediately after bathing within 3 minutes ("soak and seal" method) to trap water within the stratum corneum.
   • Precaution: Avoid thick petrolatum directly underneath silicone sheeting or custom pressure garments if it causes maceration or garment slippage.
2. Bathing & Temperature Modification:
   • Bathe strictly in lukewarm or tepid water (never hot water). High water temperatures trigger cutaneous vasodilation and massive thermal mast cell degranulation, producing severe itch flares.
   • Use mild, synthetic detergent (syndet) soap-free cleansers with neutral pH (5.5).
   • Apply clean, cool, moist compresses ($15^{\circ}\text{C}$ to $20^{\circ}\text{C}$) to acutely itching grafted zones to stimulate cold-sensitive A-delta fibers, which centrally inhibit C-fiber itch transmission in the dorsal horn.
3. Mechanical Trauma Protection:
   • Keep the patient's fingernails trimmed short and filed smooth.
   • Provide soft 100% cotton gloves for patients to wear during sleep to prevent unconscious nighttime excoriation.
   • Educate patients to apply gentle manual palm pressure, tap, or stroke intact skin instead of scratching with sharp fingernails.
   • Dress in loose-fitting, soft, 100% cotton garments; avoid scratchy synthetic fibers or wool.

---

4. Step 2: Combination Oral Antihistamine Protocols

Antihistamines are foundational during the early histaminergic phase. Monotherapy with a single H1 blocker is frequently inadequate because dermal microvasculature contains both H1 and H2 receptors.

                    SYNERGISTIC DUAL HISTAMINE BLOCKADE
  ┌────────────────────────────────────────────────────────────────────────┐
  │ Mast Cell Degranulation Releases Histamine into Extracellular Space    │
  │                                    │                                   │
  │                 ┌──────────────────┴──────────────────┐                │
  │                 ▼                                     ▼                │
  │     H1 RECEPTORS ON C-FIBERS              H2 RECEPTORS ON DERMAL       │
  │     & DERMAL ENDOTHELIUM                  VASCULAR SMOOTH MUSCLE       │
  │     • Pruritus signaling transmission     • Arteriolar vasodilation    │
  │     • Capillary permeability / edema      • Enhanced mediator washout  │
  │                 │                                     │                │
  │                 ▼                                     ▼                │
  │     BLOCKED BY: Cetirizine /              BLOCKED BY: Famotidine /     │
  │     Hydroxyzine / Fexofenadine            Cimetidine                   │
  └────────────────────────────────────────────────────────────────────────┘

Clinical Antihistamine Regimens:

• Second-Generation H1 Antagonists (Daytime): Cetirizine (10 to 20 mg PO daily) or Fexofenadine (180 mg PO daily). These agents have high H1 receptor selectivity and minimal blood-brain barrier penetration, providing daytime relief without causing debilitating daytime sedation.
• First-Generation H1 Antagonists (Nighttime): Hydroxyzine (25 to 50 mg PO at bedtime) or Diphenhydramine (25 to 50 mg PO qHS). Their central sedating and anticholinergic properties help suppress nocturnal itch and facilitate sleep.
• H2 Receptor Antagonists (Adjunctive Synergists): Famotidine (20 mg PO BID) or Cimetidine (400 mg PO BID). Adding an H2 blocker suppresses H2-mediated cutaneous vasodilation, providing synergistic relief in refractory cases.

---

5. Step 3: Central Neuropathic Modulators (Gabapentinoids)

When pruritus persists beyond the acute inflammatory phase or proves refractory to antihistamines, it is driven by neuropathic central sensitization. Gabapentinoids are the undisputed gold standard for neuropathic post-burn pruritus.

Mechanism of Action:

Gabapentin and pregabalin bind with high affinity to the $\alpha_2\delta$ (alpha-2-delta) auxiliary subunit of voltage-gated calcium channels in the dorsal horn of the spinal cord. This blocks calcium influx into presynaptic sensory terminals, suppressing the exocytosis of excitatory neurotransmitters (glutamate, substance P, and CGRP) and blunting the central transmission of itch signals to the thalamus.

                     GABAPENTIN DOSING & TITRATION PROTOCOL
  ┌────────────────────────────────────────────────────────────────────────┐
  │ Initial Dose: 100 to 300 mg PO at bedtime (titrated to minimize ataxia)│
  │                                   │                                    │
  │                                   ▼                                    │
  │ Progressive Escalation: 300 mg PO TID (900 mg/day) over 3–5 days       │
  │                                   │                                    │
  │                                   ▼                                    │
  │ Therapeutic Target: 300 to 600 mg PO TID (900 to 1800 mg/day)          │
  │ (Maximum Burn Dosing: up to 2400–3600 mg/day divided TID)              │
  │                                   │                                    │
  │                                   ▼                                    │
  │ MANDATORY CLINICAL ADJUSTMENTS:                                        │
  │ • Renal Impairment: Reduce dose proportionally based on Creatinine Cl  │
  │ • Adverse Effects: Monitor for sedation, dizziness, peripheral edema   │
  │ • Discontinuation: Taper slowly over 1–2 weeks to prevent withdrawal   │
  └────────────────────────────────────────────────────────────────────────┘

• Pregabalin (Lyrica): Provides faster linear absorption and higher bioavailability; dosed at 75 to 150 mg PO BID (up to 300 mg BID).

---

6. Step 4: Specialized Topical, Systemic, and Laser Adjuncts

For severe, chronic, or refractory pruritus resisting Steps 1 through 3, specialized multimodal options are deployed: